JP7663500B2 - Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞 - Google Patents

Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞 Download PDF

Info

Publication number
JP7663500B2
JP7663500B2 JP2021546261A JP2021546261A JP7663500B2 JP 7663500 B2 JP7663500 B2 JP 7663500B2 JP 2021546261 A JP2021546261 A JP 2021546261A JP 2021546261 A JP2021546261 A JP 2021546261A JP 7663500 B2 JP7663500 B2 JP 7663500B2
Authority
JP
Japan
Prior art keywords
cells
car
cell
cldn6
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021546261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520059A (ja
Inventor
ウグル サヒン，
ペトラ オーム，
ベンジャミン レングストル，
カタリーナ ラインハルト，
クリスティーナ ミヒェル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech Cell and Gene Therapies GmbH
Original Assignee
Biontech Cell and Gene Therapies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Cell and Gene Therapies GmbH filed Critical Biontech Cell and Gene Therapies GmbH
Publication of JP2022520059A publication Critical patent/JP2022520059A/ja
Priority to JP2024230070A priority Critical patent/JP2025060882A/ja
Application granted granted Critical
Publication of JP7663500B2 publication Critical patent/JP7663500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021546261A 2019-02-08 2020-02-05 Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞 Active JP7663500B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024230070A JP2025060882A (ja) 2019-02-08 2024-12-26 Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2019/053156 2019-02-08
EP2019053156 2019-02-08
PCT/EP2020/052867 WO2020161186A1 (en) 2019-02-08 2020-02-05 Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024230070A Division JP2025060882A (ja) 2019-02-08 2024-12-26 Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞

Publications (2)

Publication Number Publication Date
JP2022520059A JP2022520059A (ja) 2022-03-28
JP7663500B2 true JP7663500B2 (ja) 2025-04-16

Family

ID=69374312

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546261A Active JP7663500B2 (ja) 2019-02-08 2020-02-05 Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞
JP2024230070A Pending JP2025060882A (ja) 2019-02-08 2024-12-26 Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024230070A Pending JP2025060882A (ja) 2019-02-08 2024-12-26 Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞

Country Status (26)

Country Link
US (1) US20220184119A1 (enExample)
EP (2) EP3920939B1 (enExample)
JP (2) JP7663500B2 (enExample)
KR (1) KR20210124237A (enExample)
CN (1) CN113727720A (enExample)
AU (1) AU2020217868A1 (enExample)
BR (1) BR112021015429A2 (enExample)
CA (1) CA3129140A1 (enExample)
CL (1) CL2021002067A1 (enExample)
CO (1) CO2021010347A2 (enExample)
CU (1) CU20210067A7 (enExample)
DK (1) DK3920939T3 (enExample)
ES (1) ES3002958T3 (enExample)
FI (1) FI3920939T3 (enExample)
HR (1) HRP20250016T1 (enExample)
HU (1) HUE070174T2 (enExample)
IL (1) IL285122A (enExample)
LT (1) LT3920939T (enExample)
MX (1) MX2021009507A (enExample)
PL (1) PL3920939T3 (enExample)
PT (1) PT3920939T (enExample)
RS (1) RS66364B1 (enExample)
SG (1) SG11202108339TA (enExample)
SI (1) SI3920939T1 (enExample)
SM (1) SMT202500012T1 (enExample)
WO (1) WO2020161186A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129927A1 (en) * 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
KR20240133791A (ko) * 2021-12-09 2024-09-04 비온테크 에스이 Cldn6를 발현하는 암을 치료하기 위한 키메라 항원 수용체 변형 세포
WO2024046572A1 (en) * 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
CN114478802B (zh) * 2022-01-28 2023-05-26 郑州大学 一种嵌合抗原受体及其应用
CN114410588B (zh) * 2022-01-29 2022-11-04 西安电子科技大学 一种α1β1整合素依赖增强型CAR巨噬细胞及其制备方法和应用
CN119654342B (zh) * 2022-07-28 2025-07-18 乐普创一生物科技（上海）有限公司 抗MerTK抗体及其用途
KR20250046264A (ko) * 2022-07-29 2025-04-02 레전드 바이오테크 아일랜드 리미티드 클라우딘6 겹합 모이어티 및 이의 용도
WO2024088325A1 (zh) * 2022-10-25 2024-05-02 科济生物医药（上海）有限公司 抗体及其应用
WO2025184170A1 (en) 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106146666A (zh) 2015-03-26 2016-11-23 科济生物医药（上海）有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
JP2017500869A (ja) 2013-12-19 2017-01-12 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用
JP2017518762A (ja) 2014-04-01 2017-07-13 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｃｅｌｌ ＆ Ｇｅｎｅ Ｔｈｅｒａｐｉｅｓ Ｇｍｂｈ クローディン６特異的免疫受容体およびｔ細胞エピトープ
JP2017535283A (ja) 2014-11-05 2017-11-30 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｃｌｄｎキメラ抗原受容体および使用方法
JP2018515518A (ja) 2015-05-11 2018-06-14 バイオンテック・セル・アンド・ジーン・セラピーズ・ゲーエムベーハー 核酸ワクチン接種によるｃａｒ操作ｔ細胞の効果の増強

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
JP7654240B2 (ja) * 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
CN109206524B (zh) * 2018-09-25 2022-04-05 山东兴瑞生物科技有限公司 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500869A (ja) 2013-12-19 2017-01-12 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用
JP2017518762A (ja) 2014-04-01 2017-07-13 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｃｅｌｌ ＆ Ｇｅｎｅ Ｔｈｅｒａｐｉｅｓ Ｇｍｂｈ クローディン６特異的免疫受容体およびｔ細胞エピトープ
JP2017535283A (ja) 2014-11-05 2017-11-30 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｃｌｄｎキメラ抗原受容体および使用方法
CN106146666A (zh) 2015-03-26 2016-11-23 科济生物医药（上海）有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
JP2018515518A (ja) 2015-05-11 2018-06-14 バイオンテック・セル・アンド・ジーン・セラピーズ・ゲーエムベーハー 核酸ワクチン接種によるｃａｒ操作ｔ細胞の効果の増強

Also Published As

Publication number Publication date
AU2020217868A1 (en) 2021-08-12
JP2025060882A (ja) 2025-04-10
ES3002958T3 (en) 2025-03-10
PT3920939T (pt) 2025-01-08
RS66364B1 (sr) 2025-01-31
LT3920939T (lt) 2025-01-10
EP3920939B1 (en) 2024-11-13
CU20210067A7 (es) 2022-03-07
EP4501351A3 (en) 2025-05-07
CO2021010347A2 (es) 2022-01-17
MX2021009507A (es) 2021-09-08
FI3920939T3 (fi) 2025-01-03
PL3920939T3 (pl) 2025-02-17
CA3129140A1 (en) 2020-08-13
CL2021002067A1 (es) 2022-03-11
DK3920939T3 (da) 2025-01-13
HUE070174T2 (hu) 2025-05-28
SI3920939T1 (sl) 2025-03-31
CN113727720A (zh) 2021-11-30
SG11202108339TA (en) 2021-08-30
WO2020161186A1 (en) 2020-08-13
SMT202500012T1 (it) 2025-03-12
BR112021015429A2 (pt) 2021-10-05
KR20210124237A (ko) 2021-10-14
EP3920939A1 (en) 2021-12-15
US20220184119A1 (en) 2022-06-16
IL285122A (en) 2021-09-30
EP4501351A2 (en) 2025-02-05
JP2022520059A (ja) 2022-03-28
HRP20250016T1 (hr) 2025-03-14

Similar Documents

Publication Publication Date Title
JP7663500B2 (ja) Ｃｌｄｎ６発現癌の治療のためのキメラ抗原受容体改変細胞
JP2025124713A (ja) ＩＬ１３Ｒα２陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成ＣＡＲ
CA3020330A1 (en) Chimeric antigen receptor t cell compositions
JP7648530B2 (ja) Ｃａｒ操作されたｔ細胞およびサイトカインを含む治療
US20210269501A1 (en) Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
EP3801642A1 (en) Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
US20230000962A1 (en) Treatment involving immune effector cells genetically modified to express antigen receptors
JP7775078B2 (ja) 免疫エフェクタ細胞の特異的活性化のためのインターロイキン２受容体（ｉｌ２ｒ）およびインターロイキン２（ｉｌ２）バリアント
RU2826058C2 (ru) Модифицированные клетки с химерным антигеновым рецептором для лечения рака, экспрессирующего CLDN6
US20250025505A1 (en) Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
HK40122808A (en) Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
HK40068564B (en) Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
HK40068564A (en) Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
WO2024046572A1 (en) Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
HK40065151A (en) Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
RU2832154C2 (ru) Варианты рецептора интерлейкина-2 (il2r) и интерлейкина-2 (il2) для специфической активации иммунных эффекторных клеток
TW202444909A (zh) 用於腫瘤治療之car修飾劑的生成
EP4073109A1 (en) Car t cells that target aspergillus associated antigens

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250404

R150 Certificate of patent or registration of utility model

Ref document number: 7663500

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150